


JUNO VS
OTHER LABS

PGT **A** Seq

OUR RESULTS



PGT-A Seq method
JUNO VS OTHER LABS



Independent study conducted by Bardos et al (ASRM, 2021), comparing four PGT-A providers (one of which was Juno).
The study, involving oocyte donation cycles, confirms that Juno classifies 10-20% more embryos euploid in young patients.
Birth rates appear higher for Juno cycles (6-10%), although the study was not powered to look at that outcome.

OUR RESULTS

PGT-A Seq method JUNO VS OTHER LABS



LAB A (1st Jan 1, 2019 - 30th June, 2019).

JUNO (1st July, 2021 - 31st December, 2021).

In summary:

1. Results based on large numbers of embryos and cycles (7,583 embryos analysed by previous provider, 8,400 embryos tested by Juno)
2. **More embryos are classified euploid (normal) by Juno** (44.4% versus 39.8%, i.e. -5% increase, $p < 0.0001$)
3. **Ongoing pregnancy/live birth rate after switching to Juno was 5.2% higher** (2,300 procedures)
4. **Clinical miscarriages were reduced by more than one-third** ($p < 0.0001$).



**YOUR PARTNERS
in GENETIC HEALTH**
specialist in reproductive genetics

UK USA Spain

Juno Genetics Ltd
Winchester House, Heatley Road,
Oxford Science Park, Oxford OX4 4GE
+44 203 743 1944
junogenetics.co.uk

Juno Genetics España
Ronda Guillermo Marconi, 11-A , 1º22B
46980-Paterna, Valencia, Spain
+34 900 828 420
junogenetics.es

Juno Genetics, US Inc.
140 Allen Road, Suite 300
Basking Ridge, NJ 07920
+1 908 495 1111
junogenetics.com